Author

T. Monteverde

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Assay:imaging· 1 Approach:machine learning (classical)· 1

Frequent Co-Authors

A. Bender· 1 shared A. Hedley· 1 shared A. Hock· 1 shared A. Martinsson· 1 shared B. Kruspig· 1 shared C. Dick· 1 shared C. Martins· 1 shared C. Nixon· 1 shared

Activity by Year

2018-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. Bender

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Cell morphological profiling enables high-throughput screening for PROteolysis TArgeting Chimera (PROTAC) phenotypic signature

K. Moreau, M.-A. Trapotsi, E. Mouchet, G. Williams, T. Monteverde, K. Juhani, R. Turkki, F. Miljkovic, A. Martinsson, L. Mervin, E. Mullers, I. Barrett, O. Engkvist, A. Bender

This study uses cell morphological profiling to identify phenotypic signatures of PROTACs, revealing mitotoxicity that cannot be predicted from individual components.

bioRxiv · Jan 17, 2022Pharmacology & Toxicology

Asbestos accelerates disease onset in a genetic model of Malignant Pleural Mesothelioma

P. Farahmand, K. Gyuraszova, C. Rooney, X. L. Raffo-Iraolagoitia, E. Johnson, T. Chernova, T. Monteverde, K. Blyth, R. Duffin, L. M. Carlin, D. Lewis, J. Le Quesne, M. MacFarlane, D. J. Murphy

This study shows asbestos accelerates mesothelioma onset and increases tumor burden in a genetic mouse model, with increased macrophage infiltration, but macrophage suppression did not improve survival.

bioRxiv · Jun 16, 2020Cancer Biology

The ERBB network facilitates KRAS-driven lung tumorigenesis

B. Kruspig, T. Monteverde, S. Neidler, A. Hock, E. Kerr, C. Nixon, W. Clark, A. Hedley, C. Dick, K. Vousden, C. Martins, D. Murphy

This study shows that the ERBB network is required for KRAS-driven lung tumorigenesis and that inhibiting it enhances MEK inhibitor efficacy in treating such cancers.

bioRxiv · Apr 9, 2018Cancer Biology